Future developments in the management of malignant pleural mesothelioma.
about
Loss of the deubiquitylase BAP1 alters class I histone deacetylase expression and sensitivity of mesothelioma cells to HDAC inhibitors.Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma.Blockade of aquaporin 1 inhibits proliferation, motility, and metastatic potential of mesothelioma in vitro but not in an in vivo modelWhich type of surgery should become the preferred procedure for malignant pleural mesothelioma: extrapleural pneumonectomy or extended pleurectomy?Induction chemotherapy vs post-operative adjuvant therapy for malignant pleural mesothelioma.Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma.
P2860
Future developments in the management of malignant pleural mesothelioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Future developments in the management of malignant pleural mesothelioma.
@en
Future developments in the management of malignant pleural mesothelioma.
@nl
type
label
Future developments in the management of malignant pleural mesothelioma.
@en
Future developments in the management of malignant pleural mesothelioma.
@nl
prefLabel
Future developments in the management of malignant pleural mesothelioma.
@en
Future developments in the management of malignant pleural mesothelioma.
@nl
P2093
P2860
P356
P1476
Future developments in the management of malignant pleural mesothelioma.
@en
P2093
Armando Santoro
Fabio De Vincenzo
Matteo Simonelli
Paolo Andrea Zucali
P2860
P304
P356
10.1586/ERA.09.2
P577
2009-04-01T00:00:00Z